Search

Displaying results 1951 - 1960 of 10000 in total
  1. Target

    Gremlin-1

    go.drugbank.com/bio_entities/BE0011799
    TargetHumans

    Cytokine that may play an important role during carcinogenesis and metanephric kidney organogenesis, as a BMP antagonist required for early limb outgrowth and patterning in maintaining the FGF4-SHH feedback … Down-regulates the BMP4 signaling in a dose-dependent manner (By similarity). Antagonist of BMP2; inhibits BMP2-mediated differentiation of osteoblasts (in vitro) (PubMed:27036124).

    Synonyms: Increased in high glucose protein 2, Down-regulated in Mos-transformed cells protein
  2. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive … It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.

  3. Drug

    Dapsone

    go.drugbank.com/drugs/DB00250
    ApprovedInvestigational

    Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. … A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae.

    Categories: Antiinfectives for Systemic Use, Drugs for Treatment of Lepra
  4. Drug

    Ranolazine

    go.drugbank.com/drugs/DB00243
    ApprovedInvestigational

    [L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440] … [A189234] Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms.

    Products: Mar-ranolazine XR
  5. Drug

    Idelalisib

    go.drugbank.com/drugs/DB09054
    ApprovedInvestigational

    For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other … In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils

    Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors
  6. Drug

    Yohimbine

    go.drugbank.com/drugs/DB01392
    ApprovedInvestigationalVet approvedWithdrawn

    Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac.

    Categories: Drugs Used in Erectile Dysfunction, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeInternational brands: Baron-X
  7. Drug

    Dihydrocodeine

    go.drugbank.com/drugs/DB01551
    ApprovedIllicit

    Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. … It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis

    Mixtures: Poly-tussin EXCategories: Heterocyclic Compounds with 4 or More Rings, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Colestipol

    go.drugbank.com/drugs/DB00375
    Approved

    , patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not be good candidates for using the agent owing to its physical effects on the gut. … [FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia

    Categories: Compounds used in a research, industrial, or household setting, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia
  9. Drug

    Difelikefalin

    go.drugbank.com/drugs/DB11938
    ApprovedInvestigational

    [L36420,L36395] Difelikefalin was later approved by the EMA in April 2022 for the same indication.[L41665] … [A237620] Options for therapy are limited - with no FDA-approved treatments, off-label [gabapentin] was the most evidence-based and widely available treatment.

  10. Drug

    Sodium oxybate

    go.drugbank.com/drugs/DB09072
    ApprovedInvestigational

    [A251430] Due to its physiological effects, sodium oxybate is associated with a risk for substance misuse and abuse. … [A18723] For safety reasons, sodium oxybate is a controlled substance only available through a restricted program in approved countries.